LU92446I2 - Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium - Google Patents

Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium

Info

Publication number
LU92446I2
LU92446I2 LU92446C LU92446C LU92446I2 LU 92446 I2 LU92446 I2 LU 92446I2 LU 92446 C LU92446 C LU 92446C LU 92446 C LU92446 C LU 92446C LU 92446 I2 LU92446 I2 LU 92446I2
Authority
LU
Luxembourg
Prior art keywords
dolutegravir
solvate
pharmaceutically acceptable
acceptable salt
including sodium
Prior art date
Application number
LU92446C
Other languages
English (en)
French (fr)
Original Assignee
Shionogi & Co
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37215098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92446(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co, Viiv Healthcare Co filed Critical Shionogi & Co
Publication of LU92446I2 publication Critical patent/LU92446I2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU92446C 2005-04-28 2014-05-07 Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium LU92446I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005131161 2005-04-28
JP2005312076 2005-10-27
PCT/US2006/016604 WO2006116764A1 (en) 2005-04-28 2006-04-28 Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity

Publications (1)

Publication Number Publication Date
LU92446I2 true LU92446I2 (fr) 2015-10-29

Family

ID=37215098

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92446C LU92446I2 (fr) 2005-04-28 2014-05-07 Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium
LU00210C LUC00210I2 (lt) 2005-04-28 2021-06-15

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU00210C LUC00210I2 (lt) 2005-04-28 2021-06-15

Country Status (29)

Country Link
US (22) US8129385B2 (lt)
EP (9) EP1874117B8 (lt)
JP (2) JP4295353B2 (lt)
KR (4) KR101580310B1 (lt)
AU (1) AU2006239177B8 (lt)
BR (1) BRPI0610030B8 (lt)
CA (1) CA2606282C (lt)
CY (7) CY1115151T1 (lt)
DK (6) DK3372281T3 (lt)
EA (1) EA014162B1 (lt)
ES (7) ES2567197T3 (lt)
FI (1) FIC20210017I1 (lt)
FR (1) FR14C0041I2 (lt)
HK (4) HK1107227A1 (lt)
HU (6) HUE037795T2 (lt)
IL (4) IL186555A (lt)
LT (4) LT3045206T (lt)
LU (2) LU92446I2 (lt)
MA (1) MA29460B1 (lt)
MX (2) MX302718B (lt)
NL (2) NL300676I2 (lt)
NO (5) NO339525B1 (lt)
NZ (1) NZ562339A (lt)
PL (5) PL2465580T3 (lt)
PT (5) PT3372281T (lt)
SI (6) SI3045206T1 (lt)
TW (1) TWI378931B (lt)
VN (1) VN34404A1 (lt)
WO (1) WO2006116764A1 (lt)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061513A1 (en) 2003-12-24 2005-07-07 Biota Scientific Management Pty Ltd Polycyclic agents for the treatment of respiratory syncytial virus infections
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
ES2567197T3 (es) 2005-04-28 2016-04-20 Viiv Healthcare Company Derivado de carbamoilpiridona policíclico que tiene actividad inhibidora de la integrasa del VIH
JP4982482B2 (ja) 2005-05-10 2012-07-25 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｉｖインテグラ−ゼ阻害剤
AU2006299042B8 (en) 2005-10-04 2011-09-15 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa HIV integrase inhibitors
AU2006307101A1 (en) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
TWI423972B (zh) 2006-09-28 2014-01-21 Biota Scient Management 治療呼吸系融合細胞病毒感染之多環劑
BRPI0819328A8 (pt) 2007-11-15 2016-02-10 Boehringer Ingelheim Int Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos
ATE541841T1 (de) 2007-11-15 2012-02-15 Boehringer Ingelheim Int Inhibitoren der replikation des human immunodeficiency virus
EP2220046B1 (en) 2007-11-16 2014-06-18 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
WO2010011815A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
PT2320908E (pt) * 2008-07-25 2014-03-06 Shionogi & Co Pró-fármacos de dolutegravir
WO2010011818A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
ES2449752T3 (es) * 2008-07-25 2014-03-21 Viiv Healthcare Company Proceso para la preparación de un derivado de pirido[1,2-a]pirrolo[1',2':3,4]imidazo[1,2-d]piracin-8-carboxamida
KR101695807B1 (ko) * 2008-07-25 2017-01-13 비이브 헬쓰케어 컴퍼니 화합물
MX2011006241A (es) * 2008-12-11 2011-06-28 Shionogi & Co Sintesis de inhibidores de integrasa de vih de carbamoil-piridona e intermediarios.
JP5629268B2 (ja) * 2008-12-11 2014-11-19 塩野義製薬株式会社 マルトールエーテルの製造方法および中間体
ES2964383T3 (es) 2008-12-11 2024-04-05 Viiv Healthcare Co Procesos e intermedios para inhibidores de la integrasa del VIH de carbamoilpiridona
AU2014277831C1 (en) * 2008-12-11 2022-10-06 Shionogi & Co. Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
WO2010147068A1 (ja) 2009-06-15 2010-12-23 塩野義製薬株式会社 置換された多環性カルバモイルピリドン誘導体
WO2011011483A1 (en) * 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
EP2488521B1 (en) 2009-10-13 2013-12-18 Elanco Animal Health Ireland Limited Macrocyclic integrase inhibitors
AU2014202404C1 (en) * 2010-01-27 2022-06-23 Viiv Healthcare Company Antiviral therapy
AU2014202405B2 (en) * 2010-01-27 2016-02-25 Viiv Healthcare Company Antiviral therapy
KR20170078868A (ko) * 2010-01-27 2017-07-07 비이브 헬쓰케어 컴퍼니 항바이러스 치료
TWI508968B (zh) * 2010-02-08 2015-11-21 Biota Scient Management 用於治療呼吸道融合性病毒感染的化合物
JP5765965B2 (ja) * 2010-02-26 2015-08-19 日本たばこ産業株式会社 １，３，４，８−テトラヒドロ−２Ｈ−ピリド［１，２−ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての利用
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
CN102958935B (zh) 2010-04-02 2015-12-09 爱尔兰詹森科学公司 大环整合酶抑制剂
JP5766690B2 (ja) * 2010-04-12 2015-08-19 塩野義製薬株式会社 インテグラーゼ阻害活性を有するピリドン誘導体
US9073941B2 (en) 2010-06-28 2015-07-07 Academia Sinica Compounds and methods for treating tuberculosis infection
CN103154004B (zh) 2010-08-05 2016-07-06 盐野义制药株式会社 具有hiv整合酶抑制活性的化合物的制造方法
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
MX2013003139A (es) * 2010-09-24 2013-06-18 Shionogi & Co Profarmaco de derivado de carbamoilpiridona policiclica substituida.
US8796303B2 (en) 2010-11-26 2014-08-05 Biota Scientific Management Pty Ltd. Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
ES2613180T3 (es) * 2011-09-14 2017-05-23 Mapi Pharma Limited Forma amorfa de la sal sódica dolutegravir
US9200009B2 (en) 2011-10-12 2015-12-01 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
HUE035069T2 (en) 2011-12-28 2018-05-02 Global Blood Therapeutics Inc Substituted benzaldehyde compounds and their use to increase tissue oxygenation
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
ES2926068T3 (es) * 2012-12-21 2022-10-21 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
US20140221378A1 (en) 2012-12-27 2014-08-07 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR
EP2956123A1 (en) 2013-02-18 2015-12-23 ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
EP2767272A1 (en) 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
US9573965B2 (en) 2013-02-19 2017-02-21 Aurobindo Pharma Ltd Process for the preparation of Dolutegravir
PE20161035A1 (es) 2013-03-15 2016-11-13 Global Blood Therapeutics Inc Compuestos y usos de estos para la modulacion de la hemoglobina
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR20150132146A (ko) 2013-03-15 2015-11-25 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CA2903022C (en) 2013-03-15 2021-11-09 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP2986291B1 (en) 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
WO2014200880A1 (en) * 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2015001572A2 (en) * 2013-07-04 2015-01-08 Hetero Research Foundation Process for the preparation of intermediate of dolutegravir
NO2865735T3 (lt) * 2013-07-12 2018-07-21
PT3252058T (pt) * 2013-07-12 2021-03-09 Gilead Sciences Inc Compostos policíclicos-carbamoílpiridona e seu uso para o tratamento de infecções por hiv
US9856270B2 (en) * 2013-07-17 2018-01-02 Ratiopharm Gmbh Dolutegravir salts
WO2015019310A1 (en) 2013-08-07 2015-02-12 Mylan Laboratories Ltd Process for the preparation of dolute-gravir and intermediates thereof
WO2015039348A1 (en) * 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
AP2016009157A0 (en) 2013-09-27 2016-04-30 Merck Sharp & Dohme Substituted quinolizine derivatives useful as hiv integrase inhibitors
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015092752A1 (en) 2013-12-20 2015-06-25 Mylan Laboratories Ltd. Novel crystalline form of dolutegravir sodium
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
US9808428B2 (en) 2014-01-14 2017-11-07 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
US9856271B2 (en) * 2014-01-21 2018-01-02 Laurus Labs Limited Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
JP6809681B2 (ja) 2014-02-07 2021-01-06 グローバル ブラッド セラピューティクス インコーポレイテッド ２−ヒドロキシ−６−（（２−（１−イソプロピル−１ｈ−ピラゾール−５−イル）ピリジン−３−イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形
WO2015138933A1 (en) 2014-03-13 2015-09-17 Assia Chemical Industries Ltd. Solid state forms of dolutegravir sodium
CN106831819B (zh) * 2014-03-19 2019-01-04 杭州普晒医药科技有限公司 德罗格韦钠盐的晶型及其制备方法
WO2015140569A1 (en) 2014-03-20 2015-09-24 Cipla Limited Pharmaceutical composition
WO2015177537A1 (en) * 2014-05-20 2015-11-26 Cipla Limited Process for preparing polycyclic carbamoyl pyridone derivatives and intermediates thereof
TW201613936A (en) * 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI677489B (zh) * 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (lt) * 2014-06-20 2018-06-23
JPWO2016027879A1 (ja) * 2014-08-22 2017-06-01 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
WO2016057866A1 (en) 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3045461A1 (en) 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Processes for preparing dolutegravir and analogues thereof
US10730888B2 (en) 2015-02-06 2020-08-04 Mylan Laboratories Limited Process for the preparation of dolutegravir
CZ201599A3 (cs) 2015-02-13 2016-08-24 Zentiva, K.S. Pevné formy solí dolutegraviru a způsob jejich přípravy
EP3285582B1 (en) * 2015-03-26 2020-11-11 Merck Sharp & Dohme Corp. Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
ES2837383T3 (es) 2015-04-02 2021-06-30 Gilead Sciences Inc Compuestos de carbamoilpiridonas policíclicos y su utilización farmacéutica
LT3428170T (lt) * 2015-04-28 2021-02-10 Shionogi & Co., Ltd Policiklinis piridono darinys nuo gripo ir jo provaistas
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
CZ2015537A3 (cs) 2015-08-04 2017-02-15 Zentiva, K.S. Pevné formy amorfního dolutegraviru
ES2969437T3 (es) 2015-08-19 2024-05-20 Laurus Labs Ltd Polimorfos novedosos de dolutegravir y de sales del mismo
SG11201802983TA (en) 2015-11-09 2018-05-30 Gilead Sciences Inc Therapeutic compositions for treatment of human immunodeficiency virus
WO2017087257A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
TW201731509A (zh) 2015-12-04 2017-09-16 全球血液治療公司 針對２-羥基-６-（（２-（１-異丙基-１ｈ-吡唑-５-基）吡啶-３-基）甲氧基）-苯甲醛之劑量方案
WO2017106071A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
WO2017109649A1 (en) 2015-12-21 2017-06-29 Lupin Limited Process for the preparation of hiv integrase inhibitors
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
WO2017208105A1 (en) 2016-05-30 2017-12-07 Lupin Limited Novel crystalline form of dolutegravir sodium
JP7160466B2 (ja) * 2016-06-23 2022-10-25 ヴィーブ ヘルスケア カンパニー 治療薬の送達のための組成物及び方法
US20190175511A1 (en) 2016-08-08 2019-06-13 Hetero Labs Limited A Multi-Class Anti-Retroviral Composition
WO2018029561A1 (en) 2016-08-08 2018-02-15 Hetero Labs Limited Anti-retroviral compositions
CN109789144B (zh) * 2016-08-12 2022-04-15 马德拉医疗公司 蛋白激酶调节剂
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
EP3515438B1 (en) * 2016-09-21 2022-03-02 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of integrase inhibitors
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
CA3042314A1 (en) 2016-12-02 2018-06-07 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
WO2018109786A1 (en) 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
WO2018140368A1 (en) 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
US11040986B2 (en) 2017-02-16 2021-06-22 Sandoz Ag Crystalline forms of cabotegravir sodium
EP3363802B1 (en) 2017-02-16 2019-11-20 Sandoz AG Crystalline form of cabotegravir sodium
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
KR20200031658A (ko) 2017-07-21 2020-03-24 비이브 헬쓰케어 컴퍼니 Hib 감염 및 aids를 치료하기 위한 요법
WO2019048808A1 (en) 2017-09-07 2019-03-14 Cipla Limited NOVEL POLYMORPHS OF DOLUTÉGRAVIR SODIQUE
SG11202002789XA (en) 2017-10-06 2020-04-29 Shionogi & Co Stereoselective process for preparing substituted polycyclic pyridone derivatives
US11839623B2 (en) 2018-01-12 2023-12-12 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
WO2019159199A1 (en) 2018-02-16 2019-08-22 Cipla Limited Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
WO2019199756A1 (en) 2018-04-09 2019-10-17 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
TW202323254A (zh) * 2018-05-31 2023-06-16 日商鹽野義製藥股份有限公司 多環性吡啶并三𠯤衍生物
LT3805220T (lt) 2018-05-31 2024-08-26 Shionogi & Co., Ltd Policikliniai karbamoilpiridono dariniai, skirti živ gydymui
US11453669B2 (en) * 2018-05-31 2022-09-27 Shionogi & Co., Ltd. Polycyclic pyridone derivative
EP3820875B1 (en) 2018-07-12 2024-01-17 Laurus Labs Limited A process for purification of protected polycyclic carbamoylpyridone derivatives
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
JP7437051B2 (ja) 2018-10-22 2024-02-22 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 抗ウイルスプロドラッグおよびそのナノ製剤
EP4122537A1 (en) 2019-03-22 2023-01-25 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
RU2717101C1 (ru) * 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
US20230059640A1 (en) 2019-11-28 2023-02-23 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent
CA3164528A1 (en) 2019-12-09 2021-06-17 Viiv Healthcare Company Pharmaceutical compositions comprising cabotegravir
AU2021225809B2 (en) * 2020-02-24 2023-08-24 Gilead Sciences, Inc. Tetracyclic compounds for treating HIV infection
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2022051198A1 (en) 2020-09-01 2022-03-10 Viiv Healthcare Company Combination of cabotegravir and levonorgestrel
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
WO2022125378A2 (en) 2020-12-07 2022-06-16 Viiv Healthcare Company Combination therapy
CR20230315A (es) 2021-01-19 2023-09-01 Gilead Sciences Inc Compuestos de piridotriazina sustituidos y usos de estos
WO2022253294A1 (zh) 2021-06-03 2022-12-08 江苏恒瑞医药股份有限公司 具有整合酶抑制活性的吡啶酮化合物及其药用用途
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
EP4441238A1 (en) 2021-12-03 2024-10-09 VIIV Healthcare Company Process of synthesizing (r)-3-aminobutan-1-ol
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024153203A1 (en) * 2023-01-18 2024-07-25 Ascletis BioScience Co., Ltd Integrase inhibitor and use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959316A (en) * 1972-03-13 1976-05-25 Snam Progetti S.P.A. Procedure for propylene oxide synthesis
JPH0296506A (ja) 1988-09-30 1990-04-09 Daicel Chem Ind Ltd 除草剤組成物
JP2533796B2 (ja) 1988-10-18 1996-09-11 ダイセル化学工業株式会社 ５−アルコキシピリジン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2551472B2 (ja) 1988-10-18 1996-11-06 ダイセル化学工業株式会社 ５−アルコキシ−γ−ピロン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
HUP0101999A3 (en) 1997-12-22 2003-06-30 Upjohn Co 4-hydroxyquinoline-3-carboxamides and hydrazides use of them and pharmaceutical compositions containing them
EP1297834A4 (en) † 2000-06-14 2007-05-09 Shionogi & Co ENZYME INHIBITOR HAVING TWO DIVALENT METAL IONS AS ACTIVE CENTERS
US6580562B2 (en) 2000-07-24 2003-06-17 Yazaki Corporation On-vehicle display unit
US6384263B1 (en) 2000-08-04 2002-05-07 E. I. Du Pont De Nemours And Company Process for making 3-hydroxyalkanelnitriles and conversion of the 3-hydroxyalkanelnitrile to an hydroxyaminoalkane
EP1326611B1 (en) 2000-10-12 2007-06-13 Merck & Co., Inc. Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
JP2003032772A (ja) 2001-07-12 2003-01-31 Foster Electric Co Ltd 耳掛け式イヤホン
DK3042894T1 (da) 2001-08-10 2016-11-07 Shionogi & Co Antiviralt middel
AU2002334205B2 (en) 2001-10-26 2007-07-05 Istituto Di Ricerche Di Biologia Molecolara P. Angeletti Spa Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
CN102219750B (zh) 2001-10-26 2013-05-29 P.安杰莱蒂分子生物学研究所 关于hiv整合酶的n-取代的羟基嘧啶酮甲酰胺抑制剂
DE60315796T2 (de) 2002-01-17 2008-06-05 Merck & Co., Inc. Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen
US7109186B2 (en) 2002-07-09 2006-09-19 Bristol-Myers Squibb Company HIV integrase inhibitors
EP1541558B1 (en) 2002-08-13 2008-08-13 Shionogi & Co., Ltd. Heterocyclic compounds having hiv integrase inhibitory activity
CA2498111A1 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
JP4733986B2 (ja) 2002-12-27 2011-07-27 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ＨＩＶインテグラーゼ阻害薬として有用なテトラヒドロ−４Ｈ−ピリド［１，２−ａ］ピリミジン類および関連する化合物
US6960680B2 (en) 2003-01-08 2005-11-01 Rhodia Chirex, Inc. Manufacture of water-soluble β-hydroxynitriles
JP2004244320A (ja) 2003-02-10 2004-09-02 Shionogi & Co Ltd 含窒素複素環抗ウイルス剤
EP1622615A4 (en) 2003-05-13 2009-02-18 Smithkline Beecham Corp INHIBITORS OF THE INTEGRASE OF NAPHTHYRIDINE
AU2003273190A1 (en) * 2003-08-12 2005-02-25 Rachel Beijer Scheduled message service
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP4530642B2 (ja) 2003-10-31 2010-08-25 オリンパス株式会社 内視鏡装置
EP1720856B1 (en) 2004-02-11 2013-08-14 GlaxoSmithKline LLC Hiv integrase inhibitors
CA2557785A1 (en) † 2004-03-09 2005-10-06 Merck & Co. Inc. Hiv integrase inhibitors
WO2005087766A1 (en) 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv integrase inhibitors
US7538112B2 (en) 2004-05-07 2009-05-26 Merck & Co., Inc. HIV integrase inhibitors
CA2634499A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
ATE516026T1 (de) * 2005-02-21 2011-07-15 Shionogi & Co Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung
EP1866313A1 (en) * 2005-03-31 2007-12-19 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Hiv integrase inhibitors
ES2567197T3 (es) * 2005-04-28 2016-04-20 Viiv Healthcare Company Derivado de carbamoilpiridona policíclico que tiene actividad inhibidora de la integrasa del VIH
JP2005312076A (ja) 2005-05-26 2005-11-04 Olympus Corp 電子撮像装置
WO2007019098A2 (en) 2005-08-04 2007-02-15 Smithkline Beecham Corporation Hiv integrase inhibitors
AU2006307101A1 (en) * 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase

Also Published As

Publication number Publication date
US20170224694A1 (en) 2017-08-10
ES2892304T3 (es) 2022-02-03
US20200339598A1 (en) 2020-10-29
FR14C0041I1 (lt) 2014-06-27
HUE037795T2 (hu) 2018-09-28
US20170145033A1 (en) 2017-05-25
NL300676I2 (lt) 2016-10-11
CY2021016I1 (el) 2021-10-15
VN34404A1 (en) 2013-07-25
EA200702080A1 (ru) 2008-04-28
CY2014024I2 (el) 2015-12-09
IL225207A (en) 2017-11-30
US8129385B2 (en) 2012-03-06
US20160207939A1 (en) 2016-07-21
HUS1400039I1 (hu) 2016-08-29
SI1874117T1 (sl) 2014-01-31
CY1122052T1 (el) 2020-10-14
PT1874117E (pt) 2013-10-17
NO2021018I1 (no) 2021-05-10
EP2465580A1 (en) 2012-06-20
US9273065B2 (en) 2016-03-01
CA2606282C (en) 2016-04-26
MA29460B1 (fr) 2008-05-02
ES2437268T3 (es) 2014-01-09
EP3284520B1 (en) 2019-06-05
BRPI0610030A2 (pt) 2011-10-11
US20170253616A1 (en) 2017-09-07
KR20140097438A (ko) 2014-08-06
LTC2465580I2 (lt) 2022-10-10
HUS2100022I1 (hu) 2021-07-28
HUE044978T2 (hu) 2019-11-28
ES2667868T3 (es) 2018-05-14
EP2527007A1 (en) 2012-11-28
IL225206A (en) 2017-11-30
EP3187225B1 (en) 2022-01-05
US10927129B2 (en) 2021-02-23
US20170369509A1 (en) 2017-12-28
KR101580310B1 (ko) 2016-01-04
US20240279238A1 (en) 2024-08-22
SI3372281T1 (sl) 2021-11-30
CY2021016I2 (el) 2021-12-31
EP3284520A1 (en) 2018-02-21
PT3045206T (pt) 2018-07-05
US20190152990A1 (en) 2019-05-23
CY1124601T1 (el) 2022-07-22
US20170267693A1 (en) 2017-09-21
AU2006239177B8 (en) 2012-02-16
US11267823B2 (en) 2022-03-08
CY2014024I1 (el) 2015-12-09
NL301109I2 (nl) 2021-09-15
TWI378931B (en) 2012-12-11
EP1874117A4 (en) 2009-12-30
HK1107227A1 (en) 2008-04-03
FIC20210017I1 (fi) 2021-06-10
US20150232479A1 (en) 2015-08-20
EP1874117A1 (en) 2008-01-09
KR101504998B1 (ko) 2015-03-23
HK1249742A1 (zh) 2018-11-09
US20090318421A1 (en) 2009-12-24
NZ562339A (en) 2011-01-28
NO20161315A1 (no) 2007-11-22
EP3045206B2 (en) 2023-02-15
EP3284519A1 (en) 2018-02-21
DK1874117T3 (da) 2013-09-23
PT3372281T (pt) 2021-10-14
NO340111B1 (no) 2017-03-13
US8778943B2 (en) 2014-07-15
CA2606282A1 (en) 2006-11-02
SI3187225T1 (sl) 2022-04-29
BRPI0610030B1 (pt) 2020-09-15
ES2906792T3 (es) 2022-04-20
PL3284520T3 (pl) 2020-01-31
EP3372281B1 (en) 2021-07-07
EP2527007B1 (en) 2016-03-30
JP2008540343A (ja) 2008-11-20
ES2446324T3 (es) 2014-03-07
IL186555A0 (en) 2008-01-20
EP3372281A1 (en) 2018-09-12
US20190284208A1 (en) 2019-09-19
LT3284520T (lt) 2019-09-25
US9051337B2 (en) 2015-06-09
FR14C0041I2 (fr) 2015-11-13
LT3045206T (lt) 2018-06-11
WO2006116764A1 (en) 2006-11-02
EA014162B1 (ru) 2010-10-29
DK3187225T3 (da) 2022-02-28
NO2017010I2 (no) 2017-03-27
NO2017010I1 (no) 2017-03-27
PL1874117T3 (pl) 2014-01-31
US20120115875A1 (en) 2012-05-10
KR20160003889A (ko) 2016-01-11
NO2023042I1 (no) 2023-11-08
US20220213121A1 (en) 2022-07-07
HUE056603T2 (hu) 2022-02-28
CY1120345T1 (el) 2019-07-10
PL3045206T3 (pl) 2018-08-31
SI2465580T1 (sl) 2014-04-30
AU2006239177B2 (en) 2011-10-20
US20170029438A1 (en) 2017-02-02
MX2007013351A (es) 2008-01-21
US20170209454A1 (en) 2017-07-27
NL301109I1 (nl) 2021-09-15
DK3372281T3 (da) 2021-09-27
US20170260203A1 (en) 2017-09-14
ES2567197T3 (es) 2016-04-20
CY1115151T1 (el) 2015-12-09
US8410103B2 (en) 2013-04-02
TW200716635A (en) 2007-05-01
EP2465580B1 (en) 2013-12-18
DK3284520T3 (da) 2019-09-16
US20160304535A1 (en) 2016-10-20
DK3045206T3 (en) 2018-05-22
HK1172282A1 (en) 2013-04-19
PT3284520T (pt) 2019-09-10
EP3045206B1 (en) 2018-03-28
ES2743531T3 (es) 2020-02-19
PL3372281T3 (pl) 2021-12-27
CY1116331T1 (el) 2017-02-08
SI3284520T1 (sl) 2019-10-30
EP3045206A1 (en) 2016-07-20
EP3284519A8 (en) 2018-04-18
PL2465580T3 (pl) 2014-05-30
US20140200209A1 (en) 2014-07-17
ES2667868T5 (es) 2023-06-01
IL215788A0 (en) 2011-12-29
LTPA2021512I1 (lt) 2021-07-12
KR20130133061A (ko) 2013-12-05
PT2465580E (pt) 2014-02-25
HK1251191A1 (zh) 2019-01-25
DK2465580T3 (en) 2014-03-10
US20130172559A1 (en) 2013-07-04
MX302718B (es) 2012-08-27
KR20080009733A (ko) 2008-01-29
LT3372281T (lt) 2021-12-10
MX312216B (en) 2013-08-12
BRPI0610030B8 (pt) 2022-01-11
EP1874117B8 (en) 2014-03-12
JP2009079058A (ja) 2009-04-16
IL186555A (en) 2016-10-31
KR101848819B1 (ko) 2018-04-16
US20160137666A1 (en) 2016-05-19
EP3187226A1 (en) 2017-07-05
JP4295353B2 (ja) 2009-07-15
EP3187225A1 (en) 2017-07-05
LUC00210I2 (lt) 2022-10-07
US20170224695A1 (en) 2017-08-10
NO339525B1 (no) 2016-12-27
NO20075165L (no) 2007-11-22
AU2006239177A1 (en) 2006-11-02
EP1874117B1 (en) 2013-08-28
SI3045206T1 (en) 2018-07-31
KR101363875B1 (ko) 2014-02-21
HUS2100023I1 (hu) 2021-07-28

Similar Documents

Publication Publication Date Title
LU92446I2 (fr) Dolutégravir ou un sel ou solvate pharmaceutiquement acceptable de celui-ci, y compris de dolutégravir de sodium
LU93327I2 (fr) Opicapone ou un sel pharmaceutiquement acceptable de celui-ci
LU92568I2 (fr) Siméprévir, ou un sel de celui-ci, y compris le sodium siméprévir
NO2024010I1 (no) Gefapixant, or a pharmaceutically acceptable salt thereof
LU92702I2 (fr) Naloxegol ou un sel pharmaceutiquement acceptable de celui-ci (moventig)
NO2023047I1 (no) Cedazuridine, or a pharmaceutically acceptable salt thereof
NO2022057I1 (no) Capmatinib or a pharmaceutically acceptable salt thereof
LU92137I2 (fr) Ruxolitinib, ou un de ses sels pharmaceutiquement acceptables
NO2020038I1 (no) Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
LU92883I2 (fr) Sonidégib ou un sel, hydrate ou solvate pharmaceutiquement acceptable qui en dérive
LU93180I2 (fr) Alirocumab ou un dérivé pharmaceutiquement acceptable de celui-ci (PRALUENT)
LU93312I2 (fr) Migalastat ou un sel de celui-ci, y compris le sel de chlorhydrate
NL301106I1 (nl) Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
NO2019027I1 (no) kobicistat eller et farmasøytisk akseptabelt salt derav
NL301037I2 (nl) Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan
LU92785I2 (fr) Céritinib ou un sel pharamceutiquement acceptable de celui-ci
NO2018016I2 (no) Niraparib eller et farmasøytisk akseptabelt salt, stereoisomer eller tautomer derav
NL300703I2 (nl) Simeprevir, of een farmaceutisch aanvaardbaar zout daarvan, waaronder simeprevirnatrium.
NO2013008I2 (no) Krizotinib eller et farmasøytisk akseptabelt salt, hydrat eller solvat derav
NO2022022I1 (no) Fedratinib, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate thereof, in particular fedratinib dihydrochloride monohydrate
LU92512I2 (fr) Afoxolaner, ou un oxyde nitrique de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci
NO2016016I2 (no) Lesinurad, eller et farmasøytisk akseptabelt salt derav
LU91962I2 (fr) Azilsartan medoxomil (INN) et un de ses sels pharmaceutiquement acceptable, y compris le sel de potassium
MX2008007823A (en) Merocyanine derivatives
NL1030324A1 (nl) Sulfonylbenzimidazoolderivaten.